Drug Profile
Research programme: p16 gene therapies - Introgen
Alternative Names: INGN 221Latest Information Update: 05 Mar 2008
Price :
$50
*
At a glance
- Originator M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Aug 2002 This therapy is still in active development
- 13 Nov 1997 Preclinical development for Solid tumours in USA (Unknown route)